--- title: "Stifel Nicolaus Cuts DENTSPLY SIRONA (NASDAQ:XRAY) Price Target to $17.00" description: "Stifel Nicolaus has lowered its price target for DENTSPLY SIRONA (NASDAQ:XRAY) from $19.00 to $17.00, maintaining a \"hold\" rating. This suggests a potential upside of 33.39% from the current stock pri" type: "news" locale: "en" url: "https://longbridge.com/en/news/252339412.md" published_at: "2025-08-09T14:53:16.000Z" --- # Stifel Nicolaus Cuts DENTSPLY SIRONA (NASDAQ:XRAY) Price Target to $17.00 > Stifel Nicolaus has lowered its price target for DENTSPLY SIRONA (NASDAQ:XRAY) from $19.00 to $17.00, maintaining a "hold" rating. This suggests a potential upside of 33.39% from the current stock price. Other analysts have also adjusted their ratings, with Piper Sandler setting a target of $16.00 and Morgan Stanley at $14.00. DENTSPLY SIRONA's stock is currently trading at $12.75, with a 52-week range of $12.16 to $27.48. The company reported earnings of $0.52 per share, exceeding estimates, but revenue declined by 4.9% year-over-year. DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $19.00 to $17.00 in a report released on Friday,Benzinga reports. The brokerage presently has a "hold" rating on the medical instruments supplier's stock. Stifel Nicolaus' target price would suggest a potential upside of 33.39% from the stock's current price. - Dentsply Stock is Repricing Itself Several other analysts also recently weighed in on the stock. Piper Sandler lowered their price target on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Wall Street Zen raised shares of DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research note on Sunday, July 13th. Morgan Stanley downgraded shares of DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 price target for the company. in a research note on Tuesday, April 15th. Needham & Company LLC reissued a "hold" rating on shares of DENTSPLY SIRONA in a research note on Monday, July 21st. Finally, Barrington Research reissued an "outperform" rating and issued a $21.00 price target on shares of DENTSPLY SIRONA in a research note on Tuesday, July 22nd. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, DENTSPLY SIRONA currently has a consensus rating of "Hold" and an average price target of $19.36. Get **DENTSPLY SIRONA** alerts: **Read Our Latest Analysis on DENTSPLY SIRONA** ## DENTSPLY SIRONA Price Performance Shares of NASDAQ XRAY traded down $0.49 during mid-day trading on Friday, reaching $12.75. 847,438 shares of the company were exchanged, compared to its average volume of 2,931,700. DENTSPLY SIRONA has a 52 week low of $12.16 and a 52 week high of $27.48. The company has a quick ratio of 0.76, a current ratio of 1.10 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $2.54 billion, a PE ratio of -2.81, a PEG ratio of 0.97 and a beta of 0.94. The company's 50 day moving average price is $15.77 and its 200 day moving average price is $15.96. DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. The company had revenue of $936.00 million during the quarter, compared to the consensus estimate of $929.67 million. DENTSPLY SIRONA had a negative net margin of 24.42% and a positive return on equity of 14.31%. The firm's revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.49 EPS. Sell-side analysts forecast that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year. ## Institutional Trading of DENTSPLY SIRONA Several large investors have recently bought and sold shares of the company. Colonial Trust Co SC purchased a new position in DENTSPLY SIRONA in the 4th quarter worth approximately $26,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of DENTSPLY SIRONA during the 1st quarter valued at $25,000. Trust Co. of Toledo NA OH bought a new position in DENTSPLY SIRONA in the 2nd quarter worth $27,000. Parkside Financial Bank & Trust boosted its holdings in DENTSPLY SIRONA by 620.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier's stock worth $27,000 after buying an additional 1,477 shares during the period. Finally, Brooklyn Investment Group bought a new position in DENTSPLY SIRONA in the 1st quarter worth $26,000. 95.70% of the stock is owned by institutional investors. ## DENTSPLY SIRONA Company Profile (Get Free Report) DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform. ## Read More - Five stocks we like better than DENTSPLY SIRONA - How to Invest in Tech Stocks and Top Tech Stocks to Consider - Why Axon's 16% Surge Signals a New Era in Public Safety Tech - What is a buyback in stocks? A comprehensive guide for investors - DraftKings Posts Record Quarter, Eyes Profitability - Why is the Ex-Dividend Date Significant to Investors? - Amazon Takes an Equity Stake in IonQ—Any Upside Potential? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in DENTSPLY SIRONA Right Now? Before you consider DENTSPLY SIRONA, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list. While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [XRAY.US - Dentsply Sirona](https://longbridge.com/en/quote/XRAY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 在近期股价动量和长期疲软之后，评估登士柏西诺德（XRAY）的估值 | 登士柏西诺德（DENTSPLY SIRONA，XRAY）在过去一个月的股价上涨了 6%，在过去三个月上涨了 26%，与过去一年总回报下降 26% 形成对比。目前股价为 12.95 美元，接近其公允价值估计的 12.97 美元，表明其可能被低 | [Link](https://longbridge.com/en/news/276063911.md) | | 登士柏西诺德在新演示中展示了其连接牙科战略和产品创新 | 登士柏西诺德公司在第 44 届摩根大通医疗健康大会上展示了其连接牙科战略，强调了其在该领域的领导地位。该公司在 100 多个国家开展业务，每年培训超过 40 万名牙科专业人士，并在四年内推出了超过 50 种新产品。它在多个牙科细分市场中占据 | [Link](https://longbridge.com/en/news/275464006.md) | | 登士柏西诺德公布了其连接和数字化牙科系统的战略 | 登士柏西诺德公司发布了一份新演示文稿，概述了其市场细分、产品创新以及数字牙科的发展。该演示文稿涵盖了连接技术解决方案、基本牙科解决方案以及正畸与植牙解决方案，并提供了关于培训项目、产品发布和市场份额的统计数据。它强调了连接牙科在提高实践运营 | [Link](https://longbridge.com/en/news/275463982.md) | | Wellspect HealthCare 在美国推出 Surity 女性外部导尿管 | Wellspect HealthCare，德恩斯普利·西诺德（Dentsply Sirona Inc.）的子公司，在美国推出了 Surity 女性外部导尿管。该公司专注于创新医疗设备，旨在改善膀胱和肠道功能障碍患者的生活质量。Wellspe | [Link](https://longbridge.com/en/news/273706359.md) | | 登士柏西诺德在新演示中重点介绍了互联牙科和增长战略 | 登士柏西诺德公司在 2026 年摩根大通医疗会议上进行了展示，展示了其在连接牙科和数字牙科解决方案方面的领导地位。该公司服务于超过 100 个国家，每年培训超过 400,000 名牙科专业人士，并在四年内推出了超过 50 种新产品。主要业务 | [Link](https://longbridge.com/en/news/272512900.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.